Cytoreduction and HIPEC after neoadjuvant chemotherapy in stage IIIC–IV ovarian cancer. Critical analysis in elderly patients

Cascales-Campos, P.A.; Gil, José; Gilman, Elena; Feliciangeli, E.; López, Víctor; González, Artemio; Ruiz-Pardo, José; Nieto, Anı́bal; Parrilla, Pascual

doi:10.1016/j.ejogrb.2014.05.018

Cited by 28 publications

(15 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One study examined the effects of interval debulking after neoadjuvant chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) in the elderly with advanced ovarian cancer as an alternative to initial complex surgery. This study found that the elderly group did not receive benefit from the interval cytoreduction with HIPEC treatment and instead experienced postoperative morbidity, with the most common being grade 4 hemoperitoneum and grade 3 intra-abdominal fluid collection in 22.2% of women ( 17 ). Another study that evaluated the feasibility and safety of extensive upper abdominal surgery (EUAS) in elderly patients with advanced ovarian cancer found no significant difference to that of younger patients, and concluded that EUAS procedures are feasible in this elderly population ( 35 ).…”

Section: Methodsmentioning

confidence: 84%

See 1 more Smart Citation

The Application and Outcome of Standard of Care Treatment in Elderly Women with Ovarian Cancer: A Literature Review over the Last 10 Years

et al. 2016

View full text Add to dashboard Cite

The rising number and increasing longevity of the elderly population calls for improvements and potentially a more personalized approach to the treatment of cancer in this group. Elderly patients frequently present with a number of comorbidities, complicating surgery and chemotherapy tolerability. In the case of ovarian cancer, elderly women present with more advanced disease, making the issue of providing adequate treatment without significant morbidity critical. Most studies support the application of standard of care treatment to elderly women with ovarian cancer, yet it seems to be offered less frequently in the elderly. The objective of this review is to examine the application and outcome of standard of care treatment in elderly women with ovarian cancer. The aim is to ultimately improve the approach to treatment in this group.

show abstract

Section: Methodsmentioning

confidence: 84%

“…This was supported by other studies as well ( 23 ). Although some studies did not confirm this difference in treatment based on age ( 16 , 17 , 28 , 29 ), the bulk of the data demonstrates a disproportionate number of elderly women receiving suboptimal treatment.…”

Section: Methodsmentioning

confidence: 99%

The Application and Outcome of Standard of Care Treatment in Elderly Women with Ovarian Cancer: A Literature Review over the Last 10 Years

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Among these, 499 patients from 8 studies have homogenous clinical characteristics and represent the most homogenous population, on which conclusions can be drawn with a higher level of interest. In this population, the median overall survival is 37.3 months (range 27-78), the median disease-free survival is 14.4 months (range [12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30], and the median 5-year overall survival is 40% (range .…”

Section: Topic 6: What Is the Best Timing As Far As Results Are Concementioning

confidence: 99%

1^stEvidence-based Italian Consensus Conference on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Ovarian Cancer

Cavaliere

Cirocchi

Catena

et al. 2017

Tumori

View full text Add to dashboard Cite

Ovarian cancer (OC) remains relatively rare, although it is among the top 4 causes of cancer death for women younger than 50. The aggressive nature of the disease and its often late diagnosis with peritoneal involvement have an impact on prognosis. The current scientific literature presents ambiguous or uncertain indications for management of peritoneal carcinosis (PC) from OC, both owing to the lack of sufficient scientific data and their heterogeneity or lack of consistency. Therefore, the Italian Society of Surgical Oncology (SICO), the Italian Society of Obstetrics and Gynaecology, the Italian Association of Hospital Obstetricians and Gynaecologists, and the Italian Association of Medical Oncology conducted a multidisciplinary consensus conference (CC) on management of advanced OC presenting with PC during the SICO annual meeting in Naples, Italy, on September 10-11, 2015. An expert committee developed questions on diagnosis and staging work-up, indications, and procedural aspects for peritonectomy, systemic chemotherapy, and hyperthermic intraperitoneal chemotherapy for PC from OC. These questions were provided to 6 invited speakers who answered with an evidence-based report. Each report was submitted to a jury panel, representative of Italian experts in the fields of surgical oncology, gynecology, and medical oncology. The jury panel revised the reports before and after the open discussion during the CC. This article is the final document containing the clinical evidence reports and statements, revised and approved by all the authors before submission.

show abstract

“…28 If validated, HIPEC will need to be more cautiously studied in the elderly populations, with adequate geriatric evaluation, since in this more fragile population, the procedure might be more toxic 29 and have a higher impact on the patients' QoL.…”

Section: Discussionmentioning

confidence: 99%

Interval Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in First-Line Treatment for Advanced Ovarian Carcinoma: A Feasibility Study

Goffin

Roca

Dresse

et al. 2016

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

Cytoreduction and HIPEC after neoadjuvant chemotherapy in stage IIIC–IV ovarian cancer. Critical analysis in elderly patients

Cited by 28 publications

References 27 publications

The Application and Outcome of Standard of Care Treatment in Elderly Women with Ovarian Cancer: A Literature Review over the Last 10 Years

The Application and Outcome of Standard of Care Treatment in Elderly Women with Ovarian Cancer: A Literature Review over the Last 10 Years

1^stEvidence-based Italian Consensus Conference on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Ovarian Cancer

Interval Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in First-Line Treatment for Advanced Ovarian Carcinoma: A Feasibility Study

Contact Info

Product

Resources

About

Cytoreduction and HIPEC after neoadjuvant chemotherapy in stage IIIC–IV ovarian cancer. Critical analysis in elderly patients

Cited by 28 publications

References 27 publications

The Application and Outcome of Standard of Care Treatment in Elderly Women with Ovarian Cancer: A Literature Review over the Last 10 Years

The Application and Outcome of Standard of Care Treatment in Elderly Women with Ovarian Cancer: A Literature Review over the Last 10 Years

1stEvidence-based Italian Consensus Conference on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Ovarian Cancer

Interval Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in First-Line Treatment for Advanced Ovarian Carcinoma: A Feasibility Study

Contact Info

Product

Resources

About

1^stEvidence-based Italian Consensus Conference on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Ovarian Cancer